3Arbelle JE, Porath A. Practice guideline for the detection and management of thyroid dysfunction, A comparative review of the recommendations. Clin Endocrinol, 1999,51 ( 1 ) : 11-18.
4Kuijpens JL, Hansen B, Hamming JF, et 81. Trends in treatment and long-term survival of thyroid cancer in southeastern Netherlands, 1960-1992. Eur J Cancer, 1998,34(8) : 1235-1241.
5Coover LR, Silberstein EB, Kuhn PJ, et al. Therapeutic ^131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75. J Nucl Med, 2000,41 ( 11 ) : 1868-1875.
6US Nuclear Regulatory Commission. 10 CFR Part 35.75 : Release of individuals containing unsealed byproduct material or implants containing byproduct material. Washington, DC: US Government Printing Office, 2000.
7Friedman MI. Ghesani MI, Interactive software automates personalized radiation safety plans for Na ^131I therapy. Health Phys, 2002,83 (4):S71-84.
9Cooper DS,Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients withthyroid nodules and differentiated thyroid cancer [ J ]. Thyroid, 2009,19(11) :1167-1214.
10International Commission on Radiological Protection. ICRP Publication 94. Release of patients after therapy with unsealed radionuclides [ R ]. Netherlands : Elsevier,2004,34 ( 2 ) : 1-79.
